Lunesta vs Belsomra: Head-to-Head Efficacy Comparison

How These Two Drugs Work Differently

Eszopiclone and suvorexant represent two fundamentally different pharmacological strategies for treating insomnia. Understanding the mechanism behind each drug clarifies why their efficacy profiles diverge on measures like sleep onset, total sleep time, and next-morning alertness.

Eszopiclone, the active S-isomer of zopiclone, binds to the benzodiazepine site on GABA-A receptors. It increases inhibitory chloride ion conductance, producing sedation, anxiolysis, and muscle relaxation 1. Its half-life is approximately 6 hours, and it reaches peak plasma concentration in roughly 1 hour. The FDA approved eszopiclone in December 2004 as the first hypnotic without a limitation on duration of use, a significant departure from the 7-to-10-day restrictions placed on older Z-drugs like zolpidem 2.

Suvorexant works by a completely different pathway. Rather than enhancing inhibition, it blocks orexin-1 and orexin-2 receptors (OX1R and OX2R) in the lateral hypothalamus 3. Orexin neuropeptides (also called hypocretins) are required to sustain wakefulness. Blocking them allows the brain's natural sleep drive to proceed without the global CNS depression that GABA-ergic drugs produce. Suvorexant has a longer half-life of approximately 12 hours and was FDA-approved in August 2014 4.

The clinical implication: eszopiclone acts like a broad sedative switch. Suvorexant acts more like removing the neurological "stay awake" signal. Both produce sleep, but through opposing logic.

Sleep Onset: Which Drug Helps You Fall Asleep Faster?

Eszopiclone has a clear advantage for reducing the time it takes to fall asleep. Across multiple trials, it has produced larger reductions in latency to persistent sleep (LPS) compared with suvorexant's placebo-controlled data.

In the key 6-month trial by Krystal et al. (2003), eszopiclone 3 mg reduced subjective sleep-onset latency (sSOL) from a baseline of approximately 52.5 minutes to 26.4 minutes at month 6, a net improvement of roughly 25 minutes over placebo 1. Polysomnographic (PSG) data from earlier Phase 3 studies confirmed LPS reductions of 15 to 20 minutes at the 3 mg dose 5.

Suvorexant's registration trial (Herring et al., Lancet Neurology 2014, N=1,272) reported more modest LPS improvements. At the 40 mg dose (higher than the ultimately approved maximum of 20 mg), mean LPS fell by about 9 minutes more than placebo at month 1 on PSG 3. At the FDA-approved 20 mg dose, subjective sleep-onset improvements were statistically significant but numerically smaller than those seen with eszopiclone 3 mg.

For patients whose primary complaint is lying awake for 30 or more minutes before falling asleep, the available evidence favors eszopiclone. The speed of its GABA-ergic mechanism produces rapid sedation that the orexin-blockade pathway does not match on a minute-for-minute basis 6.

Sleep Maintenance: Staying Asleep Through the Night

The picture reverses for middle-of-the-night and early-morning awakenings. Suvorexant shows a particularly strong signal for reducing wake after sleep onset (WASO), and its longer half-life sustains this effect through the latter third of the night.

In the Herring et al. trial, suvorexant 40 mg reduced WASO by 22.1 minutes versus placebo at month 3 on PSG 3. At the 20 mg dose, WASO reductions were still statistically significant, measured at approximately 16 to 18 minutes over placebo in subsequent analyses 7. Total sleep time (TST) increased by 28 minutes over placebo at the approved dose.

Eszopiclone also improved WASO. Krystal et al. reported a WASO reduction of approximately 15 minutes versus placebo at month 6 with the 3 mg dose, along with a 45-minute net improvement in subjective total sleep time 1. These are meaningful benefits, though the WASO advantage was less pronounced than that seen with suvorexant in its own trials.

A practical decision framework: if a patient's insomnia phenotype is primarily sleep-onset difficulty, eszopiclone likely delivers faster clinical improvement. If the dominant pattern is frequent nocturnal awakenings or early terminal awakening, suvorexant's sustained orexin blockade may offer a better pharmacological match. Patients with mixed-type insomnia (both onset and maintenance problems) could reasonably trial either.

Total Sleep Time and Sleep Architecture

Beyond onset and maintenance, the two drugs differ in how they affect sleep stages. These differences matter for patients concerned about sleep quality, not just sleep quantity.

Eszopiclone increases Stage 2 (N2) non-REM sleep substantially while producing variable effects on slow-wave sleep (SWS). Most PSG studies show that SWS is preserved but not significantly increased at therapeutic doses 5. REM sleep percentage remains largely unchanged. The increase in total sleep time comes primarily from extended N2 duration, consistent with the GABA-ergic mechanism's broad cortical inhibition 8.

Suvorexant preserves a more naturalistic sleep architecture. By removing the orexin-driven wake signal rather than imposing sedation, it allows endogenous sleep-regulatory processes to determine stage distribution. Analyses of PSG data from the registration trials confirmed that suvorexant increased both REM and non-REM sleep in proportion to their natural ratios 9. REM sleep duration increased by approximately 7 to 10 minutes over placebo at month 1 with the 40 mg dose. This REM preservation is clinically relevant: REM sleep supports memory consolidation, emotional regulation, and cognitive processing.

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline noted that suvorexant "has a unique mechanism that may be preferred in patients for whom REM sleep preservation is a priority" 6. No equivalent statement was made about eszopiclone's effect on sleep architecture.

Safety and Side-Effect Profiles

Both drugs are Schedule IV controlled substances with abuse potential, but their risk profiles diverge in several clinically important ways.

Eszopiclone's most common side effects include dysgeusia (unpleasant metallic or bitter taste), reported by up to 34% of patients at the 3 mg dose 2. Dizziness, dry mouth, and next-day somnolence are also reported. The more concerning risks include complex sleep behaviors (sleepwalking, sleep-driving, sleep-eating). The FDA added a boxed warning for complex sleep behaviors to all Z-drugs, including eszopiclone, in April 2019 10. Falls are a particular concern in elderly patients. The recommended starting dose in older adults is 1 mg.

Suvorexant's most common side effects include somnolence (7% vs. 3% placebo) and headache 4. Next-day drowsiness can occur, particularly at higher doses, though the FDA specifically rejected the 40 mg dose for approval due to next-morning driving impairment concerns. Sleep paralysis and hypnagogic hallucinations have been reported at low rates (<1%), consistent with the drug's orexin-blocking mechanism (orexin deficiency is the pathophysiology of narcolepsy). Complex sleep behaviors are also listed in suvorexant's label, but the post-marketing signal has been considerably smaller than that reported for Z-drugs as a class 11.

For patients with a history of parasomnias, substance use disorder, or fall risk, suvorexant's safety profile may be more favorable. For patients who find the metallic taste of eszopiclone intolerable (a common reason for discontinuation), suvorexant eliminates that issue entirely.

Abuse Potential and Dependence

Regulatory and clinical data show that eszopiclone carries a higher abuse liability than suvorexant, though both remain in Schedule IV.

Eszopiclone produces subjective effects similar to benzodiazepines at supratherapeutic doses, including euphoria and disinhibition 12. Physical dependence can develop, and abrupt discontinuation after prolonged use has been associated with rebound insomnia lasting 1 to 2 nights 1. The Krystal et al. 6-month trial specifically assessed this: rebound insomnia was observed on nights 1 and 2 after abrupt discontinuation but resolved by night 3, with no evidence of withdrawal beyond rebound 1.

Suvorexant showed minimal evidence of physical dependence in clinical trials. In the Herring et al. study, no rebound insomnia was detected after discontinuation, and the drug's abuse-liability studies showed that recreational drug users rated suvorexant similarly to placebo for "drug liking" at the 40 mg dose 3. As Herring et al. wrote, "Suvorexant showed no signal for physical dependence, withdrawal, or rebound insomnia in trials up to 12 months in duration" 3.

For patients with a history of benzodiazepine or Z-drug misuse, suvorexant offers a pharmacologically distinct alternative with a lower dependence signal.

Drug Interactions and Special Populations

Prescribing context matters. Both drugs carry CYP-mediated interaction risks, but they involve different enzymes.

Eszopiclone is metabolized primarily by CYP3A4 and CYP2E1. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir) substantially increase eszopiclone exposure; the label recommends a maximum dose of 2 mg when co-administered with these agents 2. Concurrent CNS depressants (opioids, benzodiazepines, alcohol) amplify sedation and respiratory depression risk.

Suvorexant is also a CYP3A4 substrate, and the same class of strong inhibitors raises its plasma levels significantly. The label recommends reducing the dose to 5 mg when used with moderate CYP3A4 inhibitors and contraindicates use with strong CYP3A4 inhibitors entirely 4. Unlike eszopiclone, suvorexant is also a weak inhibitor of CYP3A4 itself, creating a theoretical (though clinically minor) bidirectional interaction potential.

Hepatic impairment. Eszopiclone exposure increases in moderate hepatic impairment; dose reduction to 2 mg maximum is recommended 2. Suvorexant has not been studied in severe hepatic impairment, but moderate impairment increased AUC by approximately 50%, prompting caution but no specific dose adjustment in the label 4.

Elderly patients. The AASM 2017 guideline conditionally recommended suvorexant for sleep-maintenance insomnia in adults (including older adults), while noting that Z-drugs "should be used at the lowest effective dose for the shortest duration in older populations due to fall risk" 6.

Cost, Insurance Coverage, and Access

Price can determine real-world drug selection as much as efficacy data does.

Eszopiclone became available as a generic in 2014 after Sepracor's (now Sunovion's) patent expiration. Generic eszopiclone costs roughly $15 to $40 for a 30-day supply at most pharmacies with a GoodRx-type discount, making it one of the more affordable prescription hypnotics 2.

Suvorexant (brand Belsomra, Merck) remained under patent protection longer, and its cash price historically exceeded $400 per month. Generic suvorexant received FDA approval in early 2023, with generic pricing gradually reducing out-of-pocket costs. Still, many insurance formularies place suvorexant on Tier 3 or require prior authorization, often mandating a trial-and-failure of a less expensive hypnotic (typically a Z-drug or trazodone) before covering it 13.

For uninsured patients or those on high-deductible plans, generic eszopiclone is significantly less expensive. This cost differential means many patients will try eszopiclone first by default, regardless of which drug's mechanism better matches their insomnia phenotype.

Guideline Recommendations

The AASM 2017 Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults provided conditional recommendations (GRADE: weak) for both eszopiclone and suvorexant 6. Neither drug received a strong recommendation, and the guideline emphasized that cognitive behavioral therapy for insomnia (CBT-I) should be the first-line treatment for all adults with chronic insomnia.

Dr. Michael Sateia, then chair of the AASM Pharmacotherapy Task Force, stated in the guideline commentary: "The evidence supports pharmacotherapy as a second-line option when CBT-I is unavailable, ineffective, or not accepted by the patient" 6.

The American College of Physicians (ACP) 2016 guideline similarly positioned drug therapy after CBT-I, adding that clinicians and patients should "use a shared decision-making approach to decide whether to add pharmacological therapy" when behavioral treatment alone is insufficient 14.

Neither guideline names one drug as superior to the other. The choice between eszopiclone and suvorexant remains a clinical judgment call based on insomnia subtype, comorbidities, prior treatment history, and formulary access.

Switching from Eszopiclone to Suvorexant (or Vice Versa)

There is no published protocol governing the switch between these two drugs. Because they act on entirely different receptor systems, cross-tapering is pharmacologically unnecessary. Standard clinical practice involves the following steps.

When switching from eszopiclone to suvorexant: discontinue eszopiclone and begin suvorexant the following night at 10 mg, titrating to 20 mg if needed after 1 to 2 weeks 4. Monitor for rebound insomnia on the first 1 to 2 nights after stopping eszopiclone, particularly if the patient has been using it nightly for more than 4 weeks.

When switching from suvorexant to eszopiclone: discontinue suvorexant and begin eszopiclone the following night. Start at 1 mg in elderly patients or 2 mg in younger adults, with titration to 3 mg if clinically indicated 2. Rebound insomnia after stopping suvorexant is rare based on trial data.

Both drugs should be taken within 30 minutes of bedtime with at least 7 hours of planned sleep remaining. Never combine them. Taking a GABA-ergic sedative and an orexin antagonist simultaneously has not been studied and carries a theoretical risk of excessive next-day sedation and impaired psychomotor function.